North America accounts for 43.3% of global home infusion therapy services revenue in 2025, USD 18.2 billion of the total, and holds that lead through 2034 as regional revenue reaches USD 36.4 billion. No other region comes close today, though the size of that lead changes over the forecast period.
Contrive Datum Insights presents this data in its report titled "Home Infusion Therapy Services Market Size, Share & Industry Analysis, By Type (Intravenous set, Needleless catheter, Infusion pump), Application (Chemotherapy, Diabetes, Hydration therapy, Inotropic therapy, Pain management, HIV therapies, Post-transplant therapies, Total parenteral nutrition, Hemophilia therapies, Others), Component (Devices & Equipment, Consumables, Services), End user (Home Care Settings, Specialty Pharmacies, Hospital-Based Home Infusion Providers, Skilled Nursing Facilities), Route of administration (Central Venous Access, Peripheral Venous Access), and Regional Forecast, 2026-2034".
Market size and how the regions compare
The global market was worth USD 42 billion in 2025 and climbs to USD 45.6 billion in 2026, then to USD 91.1 billion by 2034; that path works out to a 9.04% compound annual growth rate. Asia Pacific is the region closing distance on North America fastest: its share of global revenue rises from 21% in 2025 to 26% in 2034, with the dollar figure moving from USD 8.8 billion to USD 23.7 billion. Latin America stays the smallest region across the whole period, at 4.3% of 2025 revenue and 5% by 2034. Within North America, the United States alone accounts for USD 14.2 billion in 2025, 33.8% of the worldwide total.
What is selling within the region
Type is where the segment story sits. Infusion pump is the largest line in 2025 at 44.05% of revenue (USD 18.5 billion) and stays largest through 2034 at 45.99%. Needleless catheter grows faster than any other line, 9.61% a year, lifting its share from 20.95% to 21.95% and its value from USD 8.8 billion to USD 20 billion. Intravenous set carries 35% of 2025 revenue but grows at only 7.98%, below the market average. By application, chemotherapy leads in 2025 with 22.14% of revenue (USD 9.3 billion), while diabetes therapy grows fastest at 10.12%. Devices and equipment lead the component split in 2025 at 40% (USD 16.8 billion), with services growing fastest among components at 9.89%. Home care settings take 55% of 2025 end-user revenue (USD 23.1 billion), and central venous access accounts for 61.9% of revenue by route of administration (USD 26 billion).
North America's 43.3% share is not guaranteed to hold at that level. Asia Pacific's five-point share gain over the forecast period comes from somewhere, and the study's scenario range shows how much is riding on how fast that shift happens: a bull case built on faster payer adoption of home-based infusion reimbursement and quicker scaling of specialty pharmacy networks puts 2034 revenue at USD 97.9 billion, while a bear case, built on tighter reimbursement policy and a home infusion nursing shortage that persists longer than expected, holds it to USD 80 billion. Either scenario changes how much of the total North America is defending by the end of the forecast.
The report segments the market by type, application, component, end user and route of administration, with revenue and growth rates for every line from 2020 through 2034, country-level detail across all five regions, competitive landscape, and the methodology behind each estimate. It is delivered as a PDF; a free sample is available on request.